Nuclear IL-33 restrains the early conversion of fibroblasts to an extracellular matrix-secreting phenotype.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 01 2021
08 01 2021
Historique:
received:
11
06
2020
accepted:
11
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Interleukin (IL)-33 is a cytokine that appears to mediate fibrosis by signaling via its receptor ST2 (IL-33R/IL1RL1). It is also, however, a protein that after synthesis is sorted to the cell nucleus, where it appears to affect chromatin folding. Here we describe a novel role for nuclear IL-33 in regulating the fibroblast phenotype in murine kidney fibrosis driven by unilateral ureteral obstruction. Transcriptional profiling of IL-33-deficient kidneys 24 h after ligation revealed enhanced expression of fibrogenic genes and enrichment of gene sets involved in extracellular matrix formation and remodeling. These changes relied on intracellular effects of IL-33, because they were not reproduced by treatment with a neutralizing antibody to IL-33 that prevents IL-33R/ST2L receptor signaling nor were they observed in IL-33R/ST2-deficient kidneys. To further explore the intracellular function of IL-33, we established transcription profiles of human fibroblasts, observing that knockdown of IL-33 skewed the transcription profile from an inflammatory towards a myofibroblast phenotype, reflected in higher levels of COL3A1, COL5A1 and transgelin protein, as well as lower expression levels of IL6, CXCL8, CLL7 and CCL8. In conclusion, our findings suggest that nuclear IL-33 in fibroblasts dampens the initial profibrotic response until persistent stimuli, as enforced by UUO, can override this protective mechanism.
Identifiants
pubmed: 33420328
doi: 10.1038/s41598-020-80509-5
pii: 10.1038/s41598-020-80509-5
pmc: PMC7794291
doi:
Substances chimiques
COL3A1 protein, mouse
0
Chemokines
0
Collagen Type III
0
Il1rl1 protein, mouse
0
Interleukin-1 Receptor-Like 1 Protein
0
Interleukin-33
0
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Références
J Dermatol Sci. 2017 Feb;85(2):106-114
pubmed: 27839630
Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7249-54
pubmed: 25941360
J Cell Mol Med. 2010 Jun;14(6B):1726-39
pubmed: 19508382
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Biochem Biophys Res Commun. 2014 Aug 15;451(1):8-14
pubmed: 25003325
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Immunol. 2011 Aug 15;187(4):1609-16
pubmed: 21734074
Am J Pathol. 2010 Dec;177(6):2804-15
pubmed: 21037074
Am J Pathol. 2008 Oct;173(4):1229-42
pubmed: 18787100
Immunity. 2013 Aug 22;39(2):357-71
pubmed: 23954132
J Autoimmun. 2014 Dec;55:33-41
pubmed: 24786898
Bioinformatics. 2007 Aug 15;23(16):2183-4
pubmed: 17586828
J Allergy Clin Immunol. 2014 Dec;134(6):1422-1432.e11
pubmed: 24985397
J Immunol. 2010 Feb 1;184(3):1526-35
pubmed: 20042577
J Biol Chem. 2012 Feb 24;287(9):6941-8
pubmed: 22215666
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9021-6
pubmed: 19439663
Nat Med. 2012 Jul 06;18(7):1028-40
pubmed: 22772564
Biochem Biophys Res Commun. 2016 May 13;473(4):1026-1032
pubmed: 27067050
Gut. 2010 Apr;59(4):531-41
pubmed: 19996325
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10913-8
pubmed: 18667700
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Clin Invest. 2018 Jan 2;128(1):26-35
pubmed: 29293096
Immunity. 2015 Jun 16;42(6):1005-19
pubmed: 26084021
Bioinformation. 2008 Jul 30;2(10):428-30
pubmed: 18841237
BMC Bioinformatics. 2003 Dec 02;4:60
pubmed: 14651757
Eur J Pharmacol. 2017 Oct 5;812:18-27
pubmed: 28668506
Matrix Biol. 2018 Aug;68-69:81-93
pubmed: 29408013
J Invest Dermatol. 2015 Jul;135(7):1771-1780
pubmed: 25739051
EMBO Rep. 2008 Oct;9(10):1006-12
pubmed: 18688256
Respir Res. 2017 Jan 5;18(1):3
pubmed: 28057004